The importance of being CAFs (in cancer resistance to targeted therapies)

被引:39
作者
Rizzolio, Sabrina [1 ]
Giordano, Silvia [1 ,2 ]
Corso, Simona [1 ,2 ]
机构
[1] FPO IRCCS, Candiolo Canc Inst, Candiolo, Italy
[2] Univ Torino, Dept Oncol, Turin, Italy
关键词
CAF; targeted therapy; resistance; tumor microenvironment; FIBROBLAST ACTIVATION PROTEIN; CARCINOMA-ASSOCIATED FIBROBLASTS; STEM-LIKE CELLS; PHASE-II TRIAL; STROMAL CELLS; TUMOR-STROMA; BREAST-CANCER; T-CELLS; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY;
D O I
10.1186/s13046-022-02524-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the last two decades, clinical oncology has been revolutionized by the advent of targeted drugs. However, the efficacy of these therapies is significantly limited by primary and acquired resistance, that relies not only on cell-autonomous mechanisms but also on tumor microenvironment cues. Cancer-associated fibroblasts (CAFs) are extremely plastic cells of the tumor microenvironment. They not only produce extracellular matrix components that build up the structure of tumor stroma, but they also release growth factors, chemokines, exosomes, and metabolites that affect all tumor properties, including response to drug treatment. The contribution of CAFs to tumor progression has been deeply investigated and reviewed in several works. However, their role in resistance to anticancer therapies, and in particular to molecular therapies, has been largely overlooked. This review specifically dissects the role of CAFs in driving resistance to targeted therapies and discusses novel CAF targeted therapeutic strategies to improve patient survival.
引用
收藏
页数:16
相关论文
共 50 条
[31]   Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer [J].
Sharial, M. S. N. Mohd ;
Crown, J. ;
Hennessy, B. T. .
ANNALS OF ONCOLOGY, 2012, 23 (12) :3007-3016
[32]   Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies [J].
Gelfo, Valerio ;
Romaniello, Donatella ;
Mazzeschi, Martina ;
Sgarzi, Michela ;
Grilli, Giada ;
Morselli, Alessandra ;
Manzan, Beatrice ;
Rihawi, Karim ;
Lauriola, Mattia .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) :1-14
[33]   Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to Aid in Personalised Medicine [J].
Germano, S. ;
O'Driscoll, L. .
CURRENT CANCER DRUG TARGETS, 2009, 9 (03) :398-418
[34]   Targeted therapies and thyroid cancer: an update [J].
de la Fouchardiere, Christelle ;
Droz, Jean-Pierre .
ANTI-CANCER DRUGS, 2011, 22 (07) :688-699
[35]   Polysaccharide Nanoparticles for Targeted Cancer Therapies [J].
Peng, Peipei ;
Yang, Ke ;
Tong, Gangsheng ;
Ma, Liang .
CURRENT DRUG METABOLISM, 2018, 19 (09) :781-792
[36]   The Future of Targeted Therapies in Ovarian Cancer [J].
Banerjee, Susana ;
Gore, Martin .
ONCOLOGIST, 2009, 14 (07) :706-716
[37]   Endpoint of Cancer Treatment: Targeted Therapies [J].
Topcul, Mehmet ;
Cetin, Idil .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (11) :4395-4403
[38]   New targeted therapies in breast cancer [J].
Coussy, F. ;
Teixeira, L. ;
Giacchetti, S. ;
Cuvier, C. ;
Hocini, H. ;
Espie, M. .
GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2014, 42 (11) :787-794
[39]   Mechanisms of resistance to targeted therapies [J].
Guieze, Romain .
HEMATOLOGIE, 2020, 26 :20-26
[40]   Genomics of Resistance to Targeted Therapies [J].
Thangavadivel, Shanmugapriya ;
Woyach, Jennifer A. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (04) :715-724